The effects of blood‐brain barrier permeability on Alzheimer’s disease plasma biomarkers and their impact on clinical performance

Nattanich Pornteparak, Poosanu Thanapornsangsuth, Thanakit Pongpitakmetha, Tatchaporn Ongphichetmetha, Juthamas Rianaree, Watayuth Luechaipanit, Thanaporn Haethaisong, Adipa Chongsuksantikul, Yuttachai Likitjaroen, Thiravat Hemachudha · 2025

Read The effects of blood‐brain barrier permeability on Alzheimer’s disease plasma biomarkers and their impact on clinical performance by Nattanich Pornteparak, Poosanu Thanapornsangsuth, Thanakit Pongpitakmetha, Tatchaporn Ongphichetmetha, Juthamas Rianaree, Watayuth Luechaipanit, Thanaporn Haethaisong, Adipa Chongsuksantikul, Yuttachai Likitjaroen, Thiravat Hemachudha (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716386.txt.

Introduction

Nattanich Pornteparak and co-authors examine whether leaks in the blood-brain barrier can distort blood tests used to spot Alzheimer's disease. Their 2025 study pools people from earlier work on brain disorders with patients at a memory clinic, all of whom gave both blood and spinal fluid samples.

The team compared a barrier leak measure, the albumin quotient, between people whose blood test wrongly pointed to the disease and those it did not. The leak measure ran higher in the false positive group, among one hundred forty-seven people in total. Yet adding the leak measure to the blood marker did not predict the spinal fluid result any better than the blood marker alone. The authors say more work should test other barrier markers.

Catalog record

CREATORNattanich Pornteparak, Poosanu Thanapornsangsuth, Thanakit Pongpitakmetha, Tatchaporn Ongphichetmetha, Juthamas Rianaree, Watayuth Luechaipanit, Thanaporn Haethaisong, Adipa Chongsuksantikul, Yuttachai Likitjaroen, Thiravat Hemachudha
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11716386

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The effects of blood‐brain barrier permeability on Alzheimer’s disease plasma biomarkers and their impact on clinical performance
Authors: Nattanich Pornteparak, Poosanu Thanapornsangsuth, Thanakit Pongpitakmetha, Tatchaporn Ongphichetmetha, Juthamas Rianaree, Watayuth Luechaipanit, Thanaporn Haethaisong, Adipa Chongsuksantikul, Yuttachai Likitjaroen, Thiravat Hemachudha
Published: 2025

ABSTRACT
AbstractBackgroundThe validation of blood‐based biomarkers presents a promising role in Alzheimer's disease (AD) diagnosis owing to their accessibility and diminished invasiveness. However, despite awareness of confounding factors like kidney function, inaccuracies persist in AD diagnosis using plasma p‐tau. Notably, diverse conditions that modify blood‐brain barrier (BBB) permeability have been linked to high plasma p‐tau levels, irrespective of AD pathophysiology.MethodsData were sourced from pooling participants from preceding studies on individuals with encephalopathy and from patients attending a memory clinic, where both plasma and cerebrospinal fluid (CSF) were acquired. Stratifying participants based on binary plasma and CSF p‐tau181 results (using independently validated cut‐offs), the study compared the CSF/plasma albumin quotient (qAlb) between false positive and non‐false positive groups. Univariable linear regression predicting CSF p‐tau181 from plasma p‐tau181 was employed, facilitating the quantification of CSF p‐tau residuals for each participant. The correlations between residuals and qAlb as well as residuals and kidney were examined. A multivariable logistic regression model incorporating qAlb and plasma p‐tau181 to predict AD CSF profile was developed using encephalopathy participants and tested on the memory clinic patients.ResultsA total of 147 participants were included. The qAlb is significantly elevated in the plasma p‐tau false positive group (0.0066 vs. 0.0049, p=0.04658). A notable negative correlation exists between qAlb and CSF p‐tau residuals (Spearman rho = ‐0.0986, p = 0.0347), while no correlation was observed between kidney function and CSF p‐tau residuals (Spearman rho = ‐0.1806, p = 0.2515). Plasma p‐tau181 and qAlb predict AD in the memory clinic with the AUC of 0.78 (95% CI 0.64‐0.92), not different from using p‐tau alone (AUC 0.7778 vs 0.7759, p=0.8626).ConclusionBBB permeability influences the prediction of CSF p‐tau181 from plasma p‐tau181, notably leading to excessive level of plasma p‐tau (ie. false positives). Conversely, in evaluating the effectiveness of integrating qAlb with plasma p‐tau181 for the prediction of AD CSF profiles in clinical contexts, no difference from plasma p‐tau alone was observed. Future investigations should explore whether other biomarkers of BBB influence plasma biomarkers in a similar direction and are useful in identifying potential incorrectly classified patients.

Read the complete text